Received Nov 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Drug Exposure During Pregnancy; Drug Exposure During Pregnancy; This non-serious case was reported by a nurse via call center representative and described the occurrence of vaccine exposure during pregnancy in a 29-year-old female patient who received DTPa-IPV (Kinrix) for prophylaxis. On 13-OCT-2025, the patient received Kinrix. On 13-OCT-2025, an unknown time after receiving Kinrix, the patient experienced drug use in unapproved population (Verbatim: Drug Exposure During Pregnancy). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: Drug Exposure During Pregnancy). The outcome of the vaccine exposure during pregnancy and drug use in unapproved population were not applicable. Pregnancy exposure: Pregnancy Exposure (Kinrix): To mother in third trimester Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 22-OCT-2025 Reporter asked for safety profiles for a 29 year old female patient who was 29 weeks pregnant, the dose given on 10/13/2025. they requested and insisted on receiving safety data and declined to give follow/up data.